Close
Previous Clinical Trials
Diagram of Drug Development Process

We at BluePearl Veterinary Partners pride ourselves on being on the forefront of veterinary medicine. We frequently participate in clinical trails because we’re excited to be a part of the advancements being made in our field.

Clinical trials are research studies that test new treatments or drugs to find out if they are safe, effective, and better than the current standard treatment. Participating in a clinical trial is voluntary. No patient ever participates in a clinical trial without the owner’s express, written permission.

Below are some of the clinical trials our hospitals and doctors have been involved with:

New Medication for Anemic Cats:

BluePearl Veterinary Partners in Florida, Kansas City, Kentucky, Michigan, Virginia and Texas participated in a fully-funded clinical trial to evaluate the safety and efficacy of an oral medication to manage anemia associated with chronic kidney disease in cats. The study consisted of two phases: the efficacy phase (28 days) and the maintenance phase (8 weeks).

Please click here to view a video with more details on the feline anemia clinical trial.

New Medication for Diabetic Cats:

BluePearl Veterinary Partners in Kansas City participated in a fully-funded clinical trial study evaluating a new medication for the treatment of feline diabetes mellitus.

New Medication for Post-Op Pain Control:

BluePearl Veterinary Partners in Florida, Texas, and Washington participated in a study to evaluate the effectiveness of a new medication to control post-op pain in dogs following cranial cruciate ligament or luxating patella repair surgery.

Medication for Heart Disease in Dogs:

BluePearl Veterinary Partners in Florida participated in a study of the efficacy of pimobendan in slowing the progression of heart disease in dogs.

Dogs with Lymphoma:

All five BluePearl Veterinary Partners hospitals in Washington: Seattle, Renton, Tacoma and Seattle Veterinary Specialists in Kirkland and Seattle participated in a partially-funded study for dogs with lymphoma, to assess the efficacy of a clinical device that injects microdoses of different cancer drugs or combinations of drugs into the patient’s own lymph node.

Dogs with Congestive Heart Failure:

BluePearl Veterinary Partners in Kansas City participated in a fully-funded study to diagnose and evaluate medications for the treatment of pulmonary edema and cardiomegaly associated with congestive heart failure (CHF) in dogs.

Evaluation of Chemotherapy with Acupuncture and Herbal Medicine:

BluePearl Veterinary Partners in Texas participated in a study to determine the therapeutic benefit of acupuncture and herbal supplements when added to a standard 16-week CHOP chemotherapy protocol for lymphoma in dogs.

New Medication for Chemotherapy-Induced Diarrhea:

BluePearl Veterinary Partners in Texas participated in a study to determine the therapeutic benefit of acupuncture and herbal supplements when added to a standard 16-week CHOP chemotherapy protocol for lymphoma in dogs.

New Medication for Diabetic Dogs:

BluePearl Veterinary Partners in Kansas City participated in a fully funded clinical trial to evaluate a once-a-day medication for the treatment of diabetes in dogs.

New Medication for Dogs With Atopic Dermatitis:

BluePearl Veterinary Partners at our Greenbrier, Virginia location, participated in a fully-funded trial to evaluate the safety and efficacy of an oral medication for the treatment of atopic dermatitis in dogs.

Medications for Dogs With Seizures Associated With Idiopathic Epilepsy:

BluePearl Veterinary Partners in Kansas City participated in a fully-funded clinical trial evaluating medications to treat seizures associated with idiopathic epilepsy in dogs.

Novel Therapeutic Agent for the Treatment of Solid Tumors in Dogs:

BluePearl Veterinary Partners in New York participated in a fully-funded clinical trial for the treatment of measurable (1cm or larger) solid tumors in dogs. The goal of this trial was to investigate the safety and potential effectiveness of a novel therapeutic agent that may shrink existing tumors and reduce or eliminate microscopic cancer cells. This study was fully-funded in regards to patient screening, treatment and management of any potential adverse effects.

Novel Therapeutic Agent for the Treatment of Mast Cell Tumors in Dogs:

BluePearl Veterinary Partners in New York participated in a fully-funded, clinical trial for the treatment of measurable mast cell tumors in dogs. The goal of this trial was to investigate the safety and potential effectiveness of a novel therapeutic agent that may shrink existing mast cell tumors and reduce or eliminate microscopic cancer cells. Patient screening, treatment, and management of any potential adverse effects was provided.

Novel Therapeutic Agent for the Treatment of Lymphoma in Dogs:

BluePearl Veterinary Partners in New York participated in a fully-funded, exploratory study for the treatment of lymphoma in dogs. The goal of the trial was to investigate the safety and anti-tumor activity of an orally administered novel therapeutic agent in dogs with lymphoma. Patient screening, treatment and management of any potential adverse effects were provided.

Novel Therapeutic Agent for the Treatment of Solid Tumors in Dogs:

BluePearl Veterinary Partners in New York participated in a trial for the treatment of solid tumors in dogs. The goal of this trial was to investigate the safety and potential effectiveness of a novel therapeutic agent that may have potential anti-cancer activity by inducing an inflammatory response within the tumor. Such a response may shrink existing tumors and reduce or eliminate microscopic cancer cells.

Oncology Appetite and Quality-of-Life Survey:

BluePearl Veterinary Partners in New York conducted a study of dogs who had been treated for cancer to determine the dogs’ frequency, severity, and duration of reduced appetite, gastroenteritis and altered quality of life.

Novel Therapeutic Agent for Treatment of Measurable Soft Tissue Sarcomas:

BluePearl Veterinary Partners in New York conducted a study of dogs with measurable soft tissue sarcoma. The trial evaluated the effectiveness of repeat doses of a novel therapeutic agent.

Novel Chemotherapy Protocol For Dogs With T-Cell Lymphoma:

BluePearl Veterinary Partners in multiple locations participated in a clinical trial for evaluation of the benefit of adding a novel antibody treatment to a chemotherapy protocol in dogs with T-cell lymphoma. Immunophenotyping, biopsy, treatment and management of any potential adverse effects were fully funded in this study.

Novel Chemotherapy Protocol For Dogs With B-Cell Lymphoma:

BluePearl Veterinary Partners in NY participated in the evaluation of the benefit of adding a novel antibody treatment to a chemotherapy protocol in dogs with B-cell lymphoma.

CRP in Dogs with Acute Abdomen Syndrome:

BluePearl Veterinary Partners in Florida participated in an investigation of the levels of C-Reactive Protein (CRP) in dogs with Acute Abdomen Syndrome.

Effective and Safe Emesis Induction in Cats:

BluePearl Veterinary Partners in Florida participated in a study of the safety and efficacy of inducing emesis in cats, with the least amount of sedation, using xylazine versus dexmedetomidine.

New Oral Medication for Diabetes Mellitus in Cats:

BluePearl Veterinary Partners in Florida and Kansas participated in a study for a new once-daily oral medication for the treatment of diabetes mellitus in cats.

New Medication for Post-op Pain Control:

BluePearl Veterinary Partners in Florida, Minnesota, and Tennessee participated in a study to evaluate the effectiveness of a novel anti-inflammatory in controlling pain in dogs following cranial cruciate ligament repair surgery.

New Medication for Addison’s Disease in Dogs:

BluePearl Veterinary Partners in Florida, Georgia, and Kansas participated in a study for a new medication to be used as replacement therapy for mineralocorticoid deficiency in dogs with primary adrenocortical insufficiency (hypoadrenocorticism, or Addison’s Disease).